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Abstract
Objective The EuroSCORE I was one of the most frequently used pre-operative risk models in cardiac surgery. In 2011
it was replaced by its successor the EuroSCORE II. This study aims to validate the EuroSCORE II and to compare its
performance with the EuroSCORE I in a Dutch hospital.
Methods The EuroSCORE II was prospectively validated in 2,296 consecutive cardiac surgery patients between 1 April
2012 and 1 January 2014. Receiver operating characteristic curves on in-hospital mortality were plotted for EuroSCORE I
and EuroSCORE II, and the area under the curve was calculated to assess discriminative power. Calibration was assessed
by comparing observed versus expected mortality. Additionally, analyses were performed in which we stratified for type
of surgery and for elective versus emergency surgery.
Results The observed mortality was 2.4% (55 patients). The discriminative power of the EuroSCORE II surpassed
that of the EuroSCORE I (area under the curve EuroSCORE II 0.871, 95% confidence interval (CI) 0.832–0.911; area
under the curve additive EuroSCORE I 0.840, CI 0.798–0.882; area under the curve logistic EuroSCORE I 0.761, CI
0.695–0.828). Both the additive and the logistic EuroSCORE I overestimated mortality (predictive mortality additive
EuroSCORE I median 5.0%, inter-quartile range 3.0–8.0%; logistic EuroSCORE I 10.7%, inter-quartile range 5.8–13.9),
while the EuroSCORE II underestimated mortality (median 1.6%, inter-quartile range 1.0–3.5). In most stratified analyses
the EuroSCORE II performed better.
Conclusion Our results show that the EuroSCORE II produces a valid risk prediction and outperforms the EuroSCORE I
in elective cardiac surgery patients.
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What’s new?
● The EuroSCORE I, developed in 1999, has been an im-
portant risk model in cardiac surgery; its successor, Eu-
roSCORE II, was presented in 2012 but has not been val-
idated in a Dutch cohort
● We performed a validation study to assess whether or not
the EuroSCORE II was a valid risk model in a Dutch
hospital
● The EuroSCORE II outperformed its predecessor in
a Dutch single-centre validation study, with the excep-
tion of emergency surgery
Introduction
In a growing population of patients undergoing cardiac
surgery (including older and more vulnerable patients), an
accurate pre-operative risk assessment has become indis-
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pensable [1]. An often-used method for risk assessment in
cardiac surgery is the European System for Cardiac Op-
erative Risk Evaluation, better known as the EuroSCORE
(ES). The first ES became available in 1999 and provided
a simple additive and logistic risk calculation model based
on European adult cardiac surgery patients, and was widely
implemented [2]. The EuroSCORE I (ESI) was validated
in the Netherlands for both short- and long-term mortality
and morbidity [3]. Over time, it became clear that the ESI
overestimated the 30-day and 90-day mortality risk [4, 5].
This overestimation was caused by improvements in peri-
operative patient care, substantially reduced mortality rates
and evoked the need for a renewed risk model [1].
In 2011 the successor of ESI, the EuroSCORE II (ESII),
was presented. As with all new risk models it is important
to externally validate this model in patients other than the
sampled patient population from which the risk model was
developed [6]. Differences in patient populations influence
the performance of risk models and determine whether or
not the model is fit for use in a particular population [7].
The validation studies that have been published so far
show ambiguous results when comparing the ESII with
other risk models like the ESI and the Society of Thoracic
Surgery (STS) score [8, 9]. Furthermore, several studies
used data which were collected before the ESII was devel-
oped, and several studies validated the study for surgical
procedures for which the ESII was not intended [10–12].
In 2003 we performed the first study validating the ESI in
cardiac surgery patients in the Netherlands [3]. As a sequel,
the present study aims to validate the ESII risk model in
patients undergoing cardiac surgery in the Netherlands and
also to compare ESII performance with the performance of
the additive and logistic ESI.
Materials andmethods
Data collection
The analyses were performed with data from the Amphia
Cardiac Surgery Blood Management Study. Details of this
study have been described earlier [13]. In this ongoing co-
hort study, peri-operative data are prospectively collected
for all consecutive cardiac surgery patients since 1997. Data
are collected in a distributed proprietary database during the
complete peri-operative course. Variables regarding pre-op-
erative co-morbidities, drug therapy, routine pre-, intra- and
post-operative laboratory analysis, complications and post-
operative outcome are collected at the Amphia Hospital in
Breda, the Netherlands. The Amphia Hospital is a non-uni-
versity hospital with the possibility of transferring special
patient categories to tertiary hospitals.
All variables necessary to calculate both the ESI and
the ESII are present in the database. After publication of
the ESII the data dictionary was updated to reflect ESII
additions and changes. The ESII update was implemented
from April 2012 on. The database is compliant with the
Dutch National Cardiac Surgery Registry and the Dutch
National Intensive Care Registry [14].
Data collection took place between 1 April 2012 and
1 January 2014.
Patient sample and analyses
All consecutive patients who underwent cardiac surgery
were included regardless of the type of surgery. For each
patient the additive and logistic ESI as well as the ESII
were calculated using the formulas available at the Eu-
roSCORE website (www.euroscore.org). The discrimina-
tive power of each risk model was assessed by plotting
the receiver operating characteristic (ROC) curves of the
different ES on in-hospital mortality, and comparing the
area under the curve (AUC). The calibration of the dif-
ferent risk models was examined comparing the observed
versus the expected values for in-hospital mortality rates.
This way we could assess whether the ES (low or high) cor-
responded with the observed mortality. We performed the
same analyses in subgroups according to type of surgery
in four categories: coronary artery bypass graft (CABG),
CABG combined with other surgery, valve surgery, mis-
cellaneous procedures and according to the urgency of the
procedure: emergency versus elective surgery. Emergency
surgery was defined as surgery which had to be performed
as soon as possible but within at least 24h after admittance.
Results
Patient characteristics
Our cohort consisted of 2,296 patients; pre- and intra-op-
erative patient characteristics are shown in Table 1. A total
of 662 patients (28.8%) were female; the median age was
70 years (inter-quartile range (IQR) 63–76). The overall
mortality in our cohort was 2.4% (55 patients).
Performance of the EuroSCORE II
We observed that although the discriminative power of
both the additive as well as the logistic ESI was good, it
was surpassed by the ES II (AUC additive ESI 0.840, 95%
confidence interval (CI) 0.798–0.882; logistic ESI 0.761,
CI 0.695–0.828; AUC ESII 0.871, CI 0.832–0.911). ROC
curves are displayed in Fig. 1. The ESII underestimated
observed mortality while the additive and the logistic ESI
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Table 1 Patient characteristics (n= 2,296)
Pre-operative variablesa Missing
Age (years) – 70 (63–76)
Female gender – 662 (28.8)
Weight (kg) – 80 (71–90)
Previous cardiac surgery – 171 (7.4)
Previous myocardial infarction – 311 (13.5)
NYHA class –
– I 942 (41.0)
– II 694 (30.2)
– III 484 (21.1)
– IV 176 (7.7)
LMCA >50% occluded 4 299 (13.0)
Left ventricular hypertrophy 24 536 (23.3)
Pulmonary artery pressure
>40mm Hg
– 58 (2.5)
Atrial fibrillation 1 399 (17.4)
Extra cardiac arteriopathy – 311 (13.5)
Hypertension 8 1,445 (62.9)
Pre-operative Hb level (g/dl) – 13.7 (12.6–14.8)
Creatinine level (µmol/l) – 84 (72–100)
Creatinine clearance – 80 (60–101)
Ejection fraction –
– good 1,758 (76.6)
– moderate 377 (16.4)
– poor 136 (5.9)
– very poor 25(1.1)
Smoking 19 366 (15.9)
Insulin-dependent diabetes – 284 (12.4)
Endocarditis – 28 (1.2)
Chronic renal failureb – 50 (2.2)
COPD – 267 (11.6)
Poor mobility – 167 (7.3)
Pre-operative use of inotropic
agents
– 25 (1.1)
Respiratory insufficiency – 65 (2.8)
Jehovah’s witnesses 2 32 (1.4)
Emergency surgery – 261 (11.4)
Aortic valve pathology – 793 (34.5)
Mitral valve pathology – 469 (20.4)
Type of surgery –
– CABG 1,059 (46.1)
– CABG + other surgery 319 (13.9)
– Valve 615 (26.8)
– Miscellaneous surgery 303 (13.2)
Off-pump procedure – 139 (6.1)
Additive EuroSCORE I – 5 (3–8)
Logistic EuroSCORE I – 10.7 (5.8–13.9)
EuroSCORE II – 1.6 (1.0–3.5)
Table 1 (Continued)
Intra-operative variables Missing
Time in surgery (min) 11 215 (180–255)
CPB time (min) – 83 (61–117)
Clamp time (min) – 54 (36–78)
Intra-operative nadir Hb (g/dl) 15 9.7 (8.4–10.8)
NYHA New York Heart Association, LMCA left main coronary artery,
COPD chronic obstructive pulmonary disease, CABG coronary artery
bypass graft
aPresented as number (%) or median (inter-quartile range)
bCreatinine level above 177mmol/l
Fig. 1 Receiver operating characteristic (ROC) curves for the additive
and logistic EuroSCORE I and the EuroSCORE II, n= 2,269
overestimated mortality (ESII observed versus expected
(O/E) ratio 1.50 vs ESI additive 0.48 vs ESI logistic 0.22;
results are displayed in Table 2).
EuroSCORE II performance in diﬀerent types of
surgery
A total of 1,059 patients underwent a CABG, 319 patients
underwent a CABG in combination with another procedure,
615 patients underwent surgery involving one or more heart
valves, and 303 patients underwent miscellaneous kinds of
cardiac surgery. Table 3 shows the observed versus expected
mortality for the different surgical procedures; the ROC
curves are presented in Fig. 2.
In patients who underwent a CABG in-hospital mortality
was 1.2%. The additive ESI had the best discriminative
power (AUC 0.900, CI 0.838–0.962) and the ESII was the
best calibrated risk model (O/E ratio ESII 0.86). In patients
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Table 2 Discrimination and calibration parameters in total cohort (n= 2,296)
Area under the curve Observed mortality Number (%) Expected mortality Median (IQR) O/E ratio
Additive EuroSCORE I 0.840 (0.798–0.882) 55 (2.4) 5.0 (3.0–8.0) 0.48
Logistic EuroSCORE I 0.761 (0.695–0.828) 55 (2.4) 10.7 (5.8–13.9) 0.22
EuroSCORE II 0.871 (0.832–0.911) 55 (2.4) 1.6 (1.0–3.5) 1.50
IQR Inter-quartile range, O/E observed versus expected
Table 3 Observed versus expected mortality for the different surgical procedures
Area under the curve Observed mortality Number (%) Expected mortality Median (IQR) O/E ratio
Discrimination and calibration according to surgical procedure
CABG (n= 1,059)
– Additive EuroSCORE I 0.900 (0.838–0.962) 13 (1.2) 4.0 (3.0–6.0) 0.30
– Logistic EuroSCORE I 0.691 (0.536–0.846) 13 (1.2) 10.6 (4.8–13.7) 0.11
– EuroSCORE II 0.884 (0.809–0.958) 13 (1.2) 1.4 (0.93–2.6) 0.86
CABG + other procedure (n= 319)
– Additive EuroSCORE I 0.739 (0.648–0.831) 14 (4.4) 7.0 (5.0–9.0) 0.63
– Logistic EuroSCORE I 0.812 (0.695–0.929) 14 (4.4) 10.3 (5.5–13.8) 0.43
– EuroSCORE II 0.693 (0.566–0.820) 14 (4.4) 3.4 (2.0–6.5) 1.29
Valve (n= 615)
– Additive EuroSCORE I 0.833 (0.722–0.943) 13 (2.1) 7.0 (5.0–9.0) 0.30
– Logistic EuroSCORE I 0.755 (0.594–0.917) 13 (2.1) 11.2 (8.8–14.2) 0.19
– EuroSCORE II 0.866 (0.768–0.964) 13 (2.1) 1.5 (1.0–3.1) 1.40
Miscellaneous procedures (n= 303)
– Additive EuroSCORE I 0.819 (0.732–0.907) 15 (5.0) 5.0 (2.0–9.0) 1.00
– Logistic EuroSCORE I 0.784 (0.692–0.876) 15 (5.0) 10.3 (4.5–14.2) 0.49
– EuroSCORE II 0.912 (0.862–0.962) 15 (5.0) 1.5 (0.7–4.7) 3.33
Discrimination and calibration according to urgency
Elective surgery (n= 2,035)
– Additive EuroSCORE I 0.827 (0.779–0.875) 30 (1.5) 5.0 (3.0–7.0) 0.30
– Logistic EuroSCORE I 0.720 (0.621–0.818) 30 (1.5) 10.5 (5.2–13.7) 0.14
– EuroSCORE II 0.839 (0.784–0.894) 30 (1.5) 1.5 (0.92–2.9) 1.00
Emergency surgery (n= 261)
– Additive EuroSCORE I 0.726 (0.616–0.836) 25 (9.6) 10.0 (7.0–13.0) 0.96
– Logistic EuroSCORE I 0.729 (0.631–0.826) 25 (9.6) 12.9 (9.2–17.5) 0.74
– EuroSCORE II 0.816 (0.736–0.896) 25 (9.6) 5.9 (2.2–13.2) 1.63
CABG Coronary artery bypass graft, IQR inter-quartile range, O/E observed versus expected
who underwent a CABG in combination with other surgery
in-hospital mortality was 4.4%. The discriminative power of
the logistic ESI was highest (AUC 0.812, CI 0.695–0.929).
Although mortality was underestimated by the ESII, the
ESI overestimated the mortality even more. Therefore the
ESII provided a better calibration (O/E ratio ESII 1.29).
In the patients who underwent isolated valve surgery
the mortality was 2.1%. The ESII had the highest dis-
criminative power and was better calibrated (AUC 0.866,
CI 0.768–0.964, O/E ratio 1.40). In patients who under-
went miscellaneous cardiac surgery, mortality was 5.0%.
The ESII showed the best discrimination (AUC 0.912, CI
0.862–0.962). The best calibration was performed by the
additive ESI (O/E ratio 1.00).
EuroSCORE II performance in emergency surgery
A total of 261 patients underwent emergency surgery and
2,035 patients underwent elective surgery. Table 3 shows
the observed versus expected mortality in patients who
underwent elective or emergency surgery (ROC curves are
displayed in Fig. 3). In patients who underwent elective
surgery the ESII had the highest discriminative power
and was best calibrated (AUC 0.839, CI 0.784–0.894,
O/E ratio1.00). In patients who underwent emergency
surgery the ESII had the highest discriminative power,
but the additive ESI was better calibrated (ESII: AUC
0.816, CI 0.736–0.896, O/E ratio 1.63; ESI: AUC 0.726,
CI 0.616–0.836, O/E ratio 0.96).
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Fig. 2 Receiver operating characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. a Patients undergoing a coronary
artery bypass graft (CABG; n= 1,059). b Patients undergoing valve surgery (n= 615). c Patients undergoing a CABG in combination with any other
procedure (n= 319). d Patients undergoing miscellaneous cardiac surgical procedures (n= 303)
Discussion
Main ﬁndings
In this validation study, we found that the ESII is a well-cal-
ibrated risk model with a good predictive value. The ESII
underestimated the mortality in some subgroups, while the
ESI overestimated the observed mortality. Nevertheless the
expected mortality of the ESII was closer to the observed
mortality than was the case for the ESI; therefore the ESII
outperformed the ESI in most patients. Whether this is also
true for patients who underwent CABG surgery in com-
bination with another procedure, miscellaneous surgery or
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Fig. 3 Receiver operating characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. a Patients undergoing elective
surgery (n= 2,035). b Patients undergoing emergency surgery (n= 261)
emergency surgery in this study is not certain due to the
small sample size of the subgroups.
Limitations and strengths
A limitation of our study is that it is a single-centre study,
which could impair the generalisability of our results. There
is little reason to believe that the patient population at the
Amphia Hospital will differ greatly from those of other
peripheral hospitals in the Netherlands. Nevertheless, bias
due to population differences could not be ruled out. Fur-
thermore, the sample sizes of some subcategories used in
our subgroup analyses (CABG in combination with another
procedure, miscellaneous surgery and emergency surgery)
might be too small to exclude random error. Also, validating
the ESII for 30-day and 90-day mortality was not possible
with our present data.
Strengths of this validation study are that our data were
collected prospectively after the implementation of the ESII
in clinical practice. The database used is accurate, and very
few data are missing.
In order to validate a risk model like the ESII, validation
studies must satisfy certain requirements. In this study we
avoided pitfalls which could lead to biased results. For ex-
ample, the ESII was developed based on data collected dur-
ing a 12-week period in 2010 and was intended for prospec-
tive use [1]. Some studies have validated the ESII based on
data acquired before 2010, and some studies included pa-
tients over an extended period of time. This could lead to
biased results because of changes and improvements made
in daily practice [15]. An example of this bias is illustrated
in a study that validates the ESII in two different time pe-
riods (R.L. Osnabrugge et al. 2012, conference abstract).
First, the ESII was validated in patients who had surgery be-
tween 2003 and 2012. The results from the analyses showed
that although the ESII had the highest discriminative power,
the STS score had a better calibration. After this analysis,
the ESII was validated in a subgroup of patients who had
surgery between 2008 and 2012. Results from these anal-
yses show that the ESII (based on patient data collected
in 2010) was the best overall risk model. Also, there are
studies in which the ESII has been validated in surgical
procedures for which the ESII was never intended (for ex-
ample in transcatheter aortic valve implantation). This also
could lead to suboptimal performance [16]. Third, some
validation studies present incomplete data or use inaccu-
rate statistical methods: for example, basing the conclusions
solely on a non-significant Hosmer-Lemeshow test, instead
of showing the complete data [17]. In our present study we
avoided these known pitfalls.
Comparison with other EuroSCORE II validation
studies
The observed in-hospital mortality in our study (2.4%) dif-
fered slightly from the overall mortality of cardiac surgery
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procedures in the Netherlands (3.0%) or in neighbouring
countries like the UK (2.7%) [17, 18]. Baseline character-
istics of our cohort and the patient sample on which the
original ESII was based were nearly identical. The only
variable that differed between our study and the original
sample was insulin-dependent diabetes (12.4% in our co-
hort versus 7.6%). The mortality rates of the original patient
sample (3.9%) and the mortality rates in our cohort differed
by 1.5%.
Ever since its publication in 2012, more than 50 stud-
ies concerning the ESII have been published with varying
results. Our results agree with a majority of these stud-
ies [19–23]. Two studies also analysed the performance of
the ESII according to type of surgery using the same cat-
egories we used. Curiously, although the ESII performed
well, these studies found that the ESI was the overall best
performing risk model in elective surgery [24, 25]. This
is due to a higher mortality rate than in our cohort. Why
the mortality of these two cohorts differs from ours is not
precisely known, but these differences could be due to dif-
ferent population characteristics such as New York Heart
Association class and gender.
In a previous study focussing solely on the performance
of the ESII in patients who had emergency surgery, the
ESII outperformed the ESI, although both showed poor cal-
ibration and discrimination [26]. In our cohort the overall
performance of the models was worse in patients who un-
derwent emergency surgery than in those who did not. In
our cohort of emergency patients the ESII had a good dis-
criminative power but a rather poor calibration, while the
additive ESI had a good calibration. It is possible that other
logistic factors, e.g. time to diagnosis or time required to
get a patient to a specialised centre, play a more impor-
tant role in the risk evaluation of emergency patients than
factors included in the ES.
One study retrospectively evaluated the performance of
the ESII in the Netherlands with similar results to ours [23].
However, this was a small study examining only 100 pa-
tients who underwent CABG surgery combined with mitral
or aortic valve surgery.
Implications for practice and future research
Before implementing a risk model in daily practice it is im-
portant to externally validate the model in local populations
[5]. Our findings show that the ESII is a good risk predic-
tor which outperforms its predecessor. Based on the results
in our cohort we recommend using the ESII as the stan-
dard tool for risk prediction in patients undergoing cardiac
surgery. A significant proportion of our cohort consisted
of patients undergoing an isolated CABG with relatively
short cardiopulmonary bypass (CPB) times. Therefore we
also recommend that all hospitals using or planning to use
ESII should validate the ESII in their setting because, for
example, differences in CPB time or operation type could
influence the predictive value of the ESII.
Another topic for future research should be identifying
other variables that could increase the accuracy of the ESII,
especially with regard to emergency surgery and/or high-
risk patients because it seems the ESII has the least predic-
tive value in those populations.
In conclusion, the ESII is a good predictive model of
short-term mortality in cardiac surgery. It is better calibrated
than its predecessor, the ESI, in patients undergoing elective
surgery.
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